Evidence map›Paper›PMID 33763601›Full record

ArticleOpen medicine (Warsaw, Poland)2021

Burkitt-like lymphoma with 11q aberration in a patient with AIDS and a patient without AIDS: Two cases reports and literature review.

Jing Wang, Li Ma, Jianghong Guo, Yanfeng Xi, Enwei Xu

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Open medicine (Warsaw, Poland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. microRNA Profile of High-Grade B-Cell Lymphoma with 11q Aberration.International journal of molecular sciences · 2024
    Article
  2. Article
  3. Review
  4. Article
  5. High-grade B-cell lymphoma with 11q aberrations: A single-center study.Journal of clinical and experimental hematopathology : JCEH · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jing WangDepartment of Pathology, Shanxi Tumor Hospital, No. 3, Kaixuan Street, Xinghualing District, Taiyuan City, Shanxi Province, China.
Li MaDepartment of Hematology, Shanxi Tumor Hospital, No. 3, Kaixuan Street, Xinghualing District, Taiyuan City, Shanxi Province, China.
Jianghong GuoDepartment of Pathology, Shanxi Tumor Hospital, No. 3, Kaixuan Street, Xinghualing District, Taiyuan City, Shanxi Province, China.
Yanfeng XiDepartment of Pathology, Shanxi Tumor Hospital, No. 3, Kaixuan Street, Xinghualing District, Taiyuan City, Shanxi Province, China.
Enwei XuDepartment of Pathology, Shanxi Tumor Hospital, No. 3, Kaixuan Street, Xinghualing District, Taiyuan City, Shanxi Province, China.
Shanxi Provincial Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study is to evaluate the clinicopathological features and the treatment of the Burkitt-like lymphoma with 11q aberration.

methodsWe reported two patients with Burkitt-like lymphoma with 11q aberration: a 56-year-old man with AIDS (case 1) and a 37-year-old woman (case 2) without AIDS. The biopsy of cervical lymph nodes showed Burkitt-like morphologic and immunophenotypic features. But both of them lack MYC rearrangement and carry an 11q-arm aberration with proximal gains and/or telomeric losses. The diagnosis was confirmed by pathological morphology, immunohistochemistry, and fluorescence

resultAfter a cycle of R-CTOEP (rituximab, cyclophosphamide, pirarubicin, vincristine, and prednisone) chemotherapy, case 1 refused to chemotherapy and radiotherapy and was followed up for 34 months without recurrence and new focus. Case 2 received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) for two cycles and achieved PR (partial response). Then, the patient in case 2 received EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) for three cycles, and the right cervical mass disappeared. She achieved complete response and was followed up for 16 months without recurrence and new focus.

conclusionBurkitt-like lymphoma with 11q abnormalities resembles Burkitt lymphoma morphologically but lacks MYC rearrangement and may have a better prognosis.

Indexed as

Burkitt-like lymphoma with 11q aberrationBurkitt lymphomaMYC rearrangementpathology

Identifiers

PMID33763601
PMCPMC7967281
OpenAlexW3137250995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.